| Home | E-Submission | Sitemap | Contact Us |  
The Korean Journal of Medicine 2009;77(2): 152-156.
내성 결핵균의 실태 및 치료
임 재 준
Current status of drug-resistant tuberculosis and its treatment
Jae-Joon Yim
Drug-resistant tuberculosis (TB), especially multidrug-resistant (MDR)-TB and extensively drug resistant (XDR)-TB, poses a serious threat to global health because it requires treatment for a long duration and frequent hospitalization, and results in a considerable number of mortalities. In South Korea, MDR is observed in 2.7% of newly diagnosed TB cases and in 14% of re-treatment cases. In addition, 5~20% of MDR-TB could be categorized as XDR-TB. Treatment regimen for MDR or XDR-TB should include 4~5 drugs susceptible to isolated tuberculous bacilli and should be maintained at least 18 months after culture conversion. Pertinent combination of anti-TB drugs and solid compliance are the basis of successful treatment for MDR and XDR-TB patients. (Korean J Med 77:152-156, 2009)
Keywords: Tuberculosis; Drug resistance; Treatment
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Supplementary Material  Supplementary Material
Current Status of Medical Disputes, Prospects and Cautions  2019 June;94(3)
Diagnosis and Treatment of Multidrug-Resistant Tuberculosis  2015 May;88(5)
Social Burden of Drug Allergy and its Prevention  2014 December;87(6)
Current Status of Primary Glomerulonephritis  2013 January;84(1)
Current Status of Tuberculosis in Korea  2011 March;82(3)
Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6791   Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association of Internal Medicine. All rights reserved.                powerd by m2community